Regeneron is trying again to get approval for its blood cancer treatment. If possible, please include the names of some medications in the explanation.
The FDA will decide whether to approve odronextamab, a treatment for relapsed or hard-to-treat follicular lymphoma, by July 30, 2025. If approved, it would join other medications like Rituxan and Gazyva, which are also used to treat this condition.